Friday, June 20, 2025 6/20/2025

Prevalence and temporal dynamics of clonal mutations associated with the risk of hematological cancer in a cohort of clinically healthy Nigerians

Award Number: K43TW011926
ORGANIZATION: FOGARTY INTERNATIONAL CENTER
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/22/2021
PERIOD OF PERFORMANCE END DATE: 05/31/2026

Group Awards By:

View Award Description

Prevalence and temporal dynamics of clonal mutations associated with the risk of hematological cancer in a cohort of clinically healthy Nigerians - PROJECT SUMMARY/ABSTRACT The burden of non-communicable diseases, especially hematological malignancies and cardiovascular diseases (CVDs), is rising in Africa. Clonal Hematopoiesis of Indeterminate Potential (CHIP) is an age-related risk factor for all-cause mortality, blood cancer and CVDs, prompting huge interests in the development of drugs targeting CHIP mutations to intercept progression to malignancies. However, individuals of African descent are a minority in these CHIP studies hence the need to understand the spectrum and frequency of CHIP variants in African populations. My long-term research goal is to generate a pan-African database of somatic mutations associated with the risk of developing myeloid leukemia. Recent genome-wide association analyses have identified germline loci predisposing individuals to increased risk of CHIP acquisition. These include the rs144418061 intergenic variant near TET2 found only in African-ancestry populations. The central hypothesis is that there is a high burden of CHIP variants in normal-aging Africans compared to age-matched healthy Caucasians. To address this, I propose the following specific aims: Aim 1 determines the frequency of CHIP mutations in a cohort of clinically healthy Nigerians. Whole blood samples from healthy Nigerian volunteers ≥40 years will be collected and error-corrected targeted sequencing will be carried out to genotype 54 genes known to be frequently mutated in myeloid malignancies. Aim 2 describes temporal trends and clinical outcomes of CHIP acquisition over a three-year period. Each subject will be followed up for three years and the temporal dynamics of CHIP clonal dominance over the period will be determined. In addition, hematological changes correlating with the CHIP architecture will be described. It is suspected that varying behavioral and clinical states will impact the rate of CHIP progression in different individuals. Aim 3 will determine the inflammatory markers associated with CHIP burden in the study population. Here, Luminex-based Human Cytokine/Chemokine assay will be adopted to tease out inflammatory signals correlating with CHIP burden. This K43 project will generate information on CHIP mutations in normal-aging Nigerians. This aligns with the study I am currently leading on CHIP burden in Nigerians with varying comorbidities. My career development goal of this K43 application is to gain skills on error-corrected sequencing, variant calling as well as data analysis and generate sufficient data for a competitive hypothesis-driven R01 submission by the fifth year of this award. This will enable me to build research capacity for blood cancer genetics in Nigeria and establish my independence as an Africa-based medical geneticist. My training and research activities will benefit from a strong committee of mentors comprising established US and Africa-based researchers in hematology, population genetics, bioinformatics and computational analysis. I will maximize my time at the Nigerian Institute of Medical Research carrying out hematological analysis and sequencing while taking advantage of hands-on training activities, important data science and research leadership courses available at the National Institutes of Health.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $88,462 )
2025	2025	NIGERIAN INSTITUTE OF MEDICAL RESEARCH	6, EDMUND CRESCENT	LAGOS				NGA	International Research and Research Training	000	5	6/9/2025	NON-COMPETING CONTINUATION	$88,462
														Subtotal = $88,462

Issue Date FY: 2024 ( Subtotal = $95,208 )
2024	2024	NIGERIAN INSTITUTE OF MEDICAL RESEARCH	6, EDMUND CRESCENT	LAGOS				NGA	International Research and Research Training	000	4	5/22/2024	NON-COMPETING CONTINUATION	$95,208
														Subtotal = $95,208

Issue Date FY: 2023 ( Subtotal = $93,972 )
2023	2023	NIGERIAN INSTITUTE OF MEDICAL RESEARCH	6 EDMUND CRESCENT	YABA, LAGOS				NGA	International Research and Research Training	000	3	6/1/2023	NON-COMPETING CONTINUATION	$93,972
														Subtotal = $93,972

Issue Date FY: 2022 ( Subtotal = $91,601 )
2022	2022	NIGERIAN INSTITUTE OF MEDICAL RESEARCH	6 EDMUND CRESCENT	YABA, LAGOS				NGA	International Research and Research Training	002	2	4/15/2022	NON-COMPETING CONTINUATION	$91,601
2022	2021	NIGERIAN INSTITUTE OF MEDICAL RESEARCH	6 EDMUND CRESCENT	YABA, LAGOS				NGA	International Research and Research Training	001	1	11/30/2021	NEW	$0
2022	2021	NIGERIAN INSTITUTE OF MEDICAL RESEARCH	6 EDMUND CRESCENT	YABA, LAGOS				NGA	International Research and Research Training	000	1	11/19/2021	NEW	$0
														Subtotal = $91,601

Issue Date FY: 2021 ( Subtotal = $93,106 )
2021	2021	NIGERIAN INSTITUTE OF MEDICAL RESEARCH	6 EDMUND CRESCENT	YABA, LAGOS				NGA	International Research and Research Training	000	1	9/17/2021	NEW	$93,106
														Subtotal = $93,106

Grand Total All Awards = $462,349

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Prevalence and temporal dynamics of clonal mutations associated with the risk of hematological cancer in a cohort of clinically healthy Nigerians

Award Number: K43TW011926

ORGANIZATION: FOGARTY INTERNATIONAL CENTER

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/22/2021

PERIOD OF PERFORMANCE END DATE: 05/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer